




The relative strengths and weaknesses of Chemomab Therapeutics Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Chemomab Therapeutics Ltd is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 411%, being 136% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	62,688	Assets	64,353
Cost of Goods Sold	0	Liabilities	2,887
Intangible Assets	0	Expenses	12,367
Liabilities, Current	2,650	Revenues	0
Liabilities, Non-Current	237	Stockholders Equity	61,466
Other Assets	1,308	Net Income	-12,478
Other Compr. Net Income	0	Comprehensive Net Income	-12,478
Other Expenses	0	BaseVar	39,859
Other Liabilities	0	ECR before LimitedLiability	361%
Other Net Income	-111	Economic Capital Ratio	411%
Other Revenues	0		
Property and Equipment	357		
Research and Development	6,334		
Selling, General and Administrative Expense	6,033		